Drug-free, on-the-go therapy for improved breathing and pain relief
Chronic nasal congestion, a symptom of chronic rhinosinusitis and rhinitis, affects 1 in every 5 people, causing them to experience constant discomfort, pain and fatigue. Current treatments are associated with limited efficacy and safety concerns.
The globally patented* and design-protected BES-1001 device is the first drug-free, non-invasive and connected treatment that provides targeted, rapid relief from nasal congestion and related pain.
Currently in clinical development, BES-1001 is expected to be registered by early 2024.
*Patents: WO2020/245467 and WO2020/245466
How it works
BES-1001 delivers precisely-modulated acoustic energy (PMAE) that gently travels through the tissue to relieve sinus and nasal congestion, pressure and pain.
Clinical validation of mechanism of action
What users are saying about BES-1001
a game-changing medical device company
We are a Swiss medical device company that develops drug-free, non-invasive medical devices for the treatment of high-prevalence chronic nasal and pain conditions. Leveraging our network of international partners, we are committed to developing medical devices that harness the power of PMAE therapy and continue to research its applications in further indications.
We aim to reshape treatment paradigms with ground-breaking therapies that are effective, safe and that meaningfully address patient convenience.